EPIX

ESSA Pharma Inc.

5.51 USD
+0.31 (+5.96%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ESSA Pharma Inc. stock is down -8.17% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 32% of the previous 27 June’s closed higher than May. 100% of analysts rate it a buy.

About ESSA Pharma Inc.

ESSA Pharma Inc. focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study. The company has collaboration agreements with Caris Life Sciences, Inc. and Bayer Consumer Care AG.